the Company

Biograil™ is a pre-clinical stage pharmaceutical company leveraging its proprietary BIONDD™ technology to unlock the potential of transforming the tremendous market of injectable pharmaceutical products into convenient oral capsules.

Proprietary Technology

Highly effective oral delivery of biologics that overcomes barriers of degradation and absorption

Verified Manufacturing Technology

Team behind Worlds first injection molded pharmaceutical product approved by the FDA

Strong Strategic Partnerships

Backed by Large International Pharmaceutical Companies, Leading Experts in Bioresorbable Polymers, Drug Device & Pharmaceutical Development

the Solution

The majority of biologic pharmaceutical products are injected, as preferred dosing by the oral route is not feasible due to degradation and poor absorption from the gut.

The BIONDD™ technology provides a viable solution to safe and highly effective dosing of biologics in a standard oral capsule.

the Technology

The BIONDD™ technology provides a platform to deliver biologics by the oral route in a standard capsule, by specifically directing the biologic drug molecule inside the stomach wall for safe and effective release to the body.

With release of the biologic drug molecule inside the stomach wall the usual barriers (degradation and poor absorption from the gut) are circumvented. This results in highly effective oral delivery of the drug equivalent to an injection.

BIONDD™ in a standard size 00 capsule

…is swallowed and is activated after 3 minutes in the stomach

The device rotates two halves in opposite direction with small spikes extending

The spikes embrace tissue from both sides and secure a safe and painless transient positioning of the spike inside the stomach wall

The biodegradable spikes detach, releasing drug from the spikes for effective distribution into the blood stream

…and throughout the body


  • Novelty of the BIONDD™ technology is emphasized by published patent application with more in progress. Reports confirm strong patent position.
  • The design of BIONDD™ secures a safe and painless transient positioning of the spike inside the stomach wall.
  • Preliminary data confirm highly effective delivery of drug from the gut wall, equivalent to an injection.


  • The design and function of BIONDD™ is strikingly elegant, and is specifically developed with manufacturing simplicity and scalability in mind.
  • Developed on the foundation of reverse engineering to secure low-cost high-volume commercial manufacturing by injection molding.
  • The Biograil™ team is behind the World’s first FDA approved drug product manufactured by injection molding.


  • BIONDD™ has potential to transform markets of injectable pharmaceutical products across a wide range of therapeutic drug classes by providing safe, effective, and convenient oral treatment of a range of diseases.
  • Patients tend to avoid injections and overwhelmingly prefer oral capsules, which results in better treatment. Contrary to injections, oral capsules are pleaseant to dose, easy to do correctly, and not stigmatizing.



Press Release: Biograil signs collaboration agreement with Janssen


Press Release: Biograil announces – Sanner Ventures has joined Investor Syndicate


CEO Karsten Lindhardt shares vision for Biograil, by MEGATREND INVEST


Press Release: Biograil Secures Seed Funding for Oral Delivery Device with Potential to Transform Market for Injectables

Biograil ApS
Baldersbuen 2
2640 Hedehusene


CVR/VAT: DK-40666699